136 related articles for article (PubMed ID: 33434900)
1. Glucocorticoid receptor-targeted liposomal delivery system for delivering small molecule ESC8 and anti-miR-Hsp90 gene construct to combat colon cancer.
Jinka S; Rachamalla HK; Bhattacharyya T; Sridharan K; Sekhar Jaggarapu MMC; Yakati V; Banerjee R
Biomed Mater; 2021 Feb; 16(2):024105. PubMed ID: 33434900
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid Receptor-Targeted Liposomal Codelivery of Lipophilic Drug and Anti-Hsp90 Gene: Strategy to Induce Drug-Sensitivity, EMT-Reversal, and Reduced Malignancy in Aggressive Tumors.
Mondal SK; Jinka S; Pal K; Nelli S; Dutta SK; Wang E; Ahmad A; AlKharfy KM; Mukhopadhyay D; Banerjee R
Mol Pharm; 2016 Jul; 13(7):2507-23. PubMed ID: 27184196
[TBL] [Abstract][Full Text] [Related]
3. Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect.
Pore SK; Choudhary A; Rathore B; Ganguly A; Sujitha P; Kumar CG; Agawane SB; Kumar JM; Scaria V; Pillai B; Banerjee R
Biomaterials; 2013 Sep; 34(28):6804-17. PubMed ID: 23773821
[TBL] [Abstract][Full Text] [Related]
4. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
5. Development of Liposomal Formulation for Delivering Anticancer Drug to Breast Cancer Stem-Cell-Like Cells and its Pharmacokinetics in an Animal Model.
Ahmad A; Mondal SK; Mukhopadhyay D; Banerjee R; Alkharfy KM
Mol Pharm; 2016 Mar; 13(3):1081-8. PubMed ID: 26832839
[TBL] [Abstract][Full Text] [Related]
6. Self-Assembling Derivative of Hydrocortisone as Glucocorticoid Receptor-Targeted Nanotherapeutics for Synergistic, Combination Therapy against Colorectal Tumor.
Sridharan K; Rathore B; Yousuf M; Reddy Rachamalla HK; Jinka S; Jaggarapu MMCS; Banerjee R
Mol Pharm; 2021 Mar; 18(3):1208-1228. PubMed ID: 33371687
[TBL] [Abstract][Full Text] [Related]
7. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
[TBL] [Abstract][Full Text] [Related]
8. Efficient anti-tumor nano-lipoplexes with unsaturated or saturated lipid induce differential genotoxic effects in mice.
Rachamalla HK; Mondal SK; Deshpande SS; Sridharan K; Javaji K; Jaggarapu MMCS; Jinka S; Bollu V; Misra S; Banerjee R
Nanotoxicology; 2019 Nov; 13(9):1161-1175. PubMed ID: 31294672
[TBL] [Abstract][Full Text] [Related]
9. Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer.
Sen K; Banerjee S; Mandal M
Colloids Surf B Biointerfaces; 2019 Aug; 180():9-22. PubMed ID: 31015105
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
11. Hybrid Nanoparticles Modified by Hyaluronic Acid Loading an HSP90 Inhibitor as a Novel Delivery System for Subcutaneous and Orthotopic Colon Cancer Therapy.
Pan C; Zhang T; Li S; Xu Z; Pan B; Xu S; Jin S; Lu G; Yang S; Xue Z; Chen P; Shen X; Wang F; Xu C
Int J Nanomedicine; 2021; 16():1743-1755. PubMed ID: 33688189
[TBL] [Abstract][Full Text] [Related]
12. A lipid-modified estrogen derivative that treats breast cancer independent of estrogen receptor expression through simultaneous induction of autophagy and apoptosis.
Sinha S; Roy S; Reddy BS; Pal K; Sudhakar G; Iyer S; Dutta S; Wang E; Vohra PK; Roy KR; Reddanna P; Mukhopadhyay D; Banerjee R
Mol Cancer Res; 2011 Mar; 9(3):364-74. PubMed ID: 21289296
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of HSP90 inhibitors for efficient therapy of CD44-positive acute myeloid leukemia and solid tumor-colon cancer.
Jia L; Yang H; Liu Y; Zhou Y; Li G; Zhou Q; Xu Y; Huang Z; Ye F; Ye J; Liu A; Ji C
J Nanobiotechnology; 2024 Apr; 22(1):198. PubMed ID: 38649957
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
15. DCZ5248, a novel dual inhibitor of Hsp90 and autophagy, exerts antitumor activity against colon cancer.
Chen XL; Liu P; Zhu WL; Lou LG
Acta Pharmacol Sin; 2021 Jan; 42(1):132-141. PubMed ID: 32404982
[TBL] [Abstract][Full Text] [Related]
16. Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo.
Patras L; Sylvester B; Luput L; Sesarman A; Licarete E; Porfire A; Muntean D; Drotar DM; Rusu AD; Nagy AL; Catoi C; Tomuta I; Vlase L; Banciu M; Achim M
Cancer Biol Ther; 2017 Aug; 18(8):616-626. PubMed ID: 28696813
[TBL] [Abstract][Full Text] [Related]
17. 3'-epi-12β-hydroxyfroside, a new cardenolide, induces cytoprotective autophagy via blocking the Hsp90/Akt/mTOR axis in lung cancer cells.
Sun Y; Huang YH; Huang FY; Mei WL; Liu Q; Wang CC; Lin YY; Huang C; Li YN; Dai HF; Tan GH
Theranostics; 2018; 8(7):2044-2060. PubMed ID: 29556372
[No Abstract] [Full Text] [Related]
18. Oestrogen receptor-mediated liposomal drug delivery for treating melanoma.
Ganguly A; Rachamalla HKR; Bhattacharya D; Bhamidipati K; Pal A; Gora Ravuri H; Chakravarty S; Adhikari SS; Banerjee R
J Drug Target; 2018; 26(5-6):481-493. PubMed ID: 29376759
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer.
Ahn JY; Lee JS; Min HY; Lee HY
Oncotarget; 2015 Oct; 6(32):32622-33. PubMed ID: 26416450
[TBL] [Abstract][Full Text] [Related]
20. Selective cancer targeting via aberrant behavior of cancer cell-associated glucocorticoid receptor.
Mukherjee A; Narayan KP; Pal K; Kumar JM; Rangaraj N; Kalivendi SV; Banerjee R
Mol Ther; 2009 Apr; 17(4):623-31. PubMed ID: 19223869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
